This article responds to “When Negotiated Prices Become The Benchmark: Prior MFPs And The Vanishing Role Of Value”, by Sean D. Sullivan, Peter J. Neumann and Emma M. Cousin, published in Health Affairs Forefront on October 8, 2026 (DOI: 10.1377/forefront.20260929.966829). That commentary argues that previously negotiated Medicare drug prices are now used as starting points in new negotiations, carrying earlier value judgments forward without re-testing them. The mechanism described below draws on that commentary; this piece sets out the implications for pricing, market access and HEOR decision-makers.

The growing use of prior MFP anchors inside Medicare drug price negotiation should command immediate attention from every senior leader responsible for health economics, market access and pricing strategies. Once an administered price from an earlier cycle becomes the default starting point for a new selected medicine, earlier judgements about comparability and discount levels travel forward largely untested. This reflection examines what that structural shift means for value-based pricing, reimbursement decisions, budget impact and long-term system dynamics, and sets out clear actions for decision-makers.

The Strategic Stakes Behind a Quiet Procedural Change

Statutory language requires the Centers for Medicare and Medicaid Services to weigh manufacturer cost data together with evidence on therapeutic alternatives, comparative effectiveness and unmet need. Guidance has translated those factors into a practical sequence that first identifies alternatives and then derives a numerical starting point from their prices. That starting point may now be the lower of net plan payment, a previously negotiated maximum fair price, or wholesale acquisition cost. For a large share of products entering the next cycle, at least one clinically related medicine already carries such a price. Because those prices remain fixed apart from inflation adjustments, the opening offer inherits an administered figure rather than a fresh reading of clinical or economic worth. The policy implications are profound: each successive cycle risks moving further from any explicit account of value.

When Reference Pricing Loses Its Market Discipline

Commercial negotiations routinely reference known net prices, yet three features separate that practice from the current Medicare approach. A commercial benchmark arises from multiple buyers, varied volumes and real outside options. An MFP is produced by one large public purchaser applying prescribed statutory factors. When that MFP re-enters a later negotiation as an input, the original choices about which medicines counted as comparable and how far to discount are carried forward without re-examination. In addition, commercial bargaining is bounded by a genuine reservation price; manufacturers can refuse to supply. Under the federal process the alternative to acceptance is severe financial penalty or loss of programme agreements, which does not function as a true reservation price. Finally, commercial pricing remains bidirectional. New evidence can support premiums or force incumbents to rebid. The Medicare rule applies a minimum operator once, after which the price largely tracks inflation. Prior MFP anchors therefore harden into durable reference points rather than living market signals.

Consequences for Value Assessment and System Dynamics

Health economics teams must now confront a process in which the dominant numerical input is often a prior administered price. Later qualitative adjustments exist precisely because the alternative may not itself reflect clinical benefit, yet no published rubric maps comparative effectiveness, unmet need or resource offsets to the size of any adjustment. The anchor performs most of the work. Over time this pattern weakens the signal that should reward meaningful therapeutic advance and complicates internal forecasts of achievable price. Budget impact models need to capture cascade effects: one low MFP can become the floor for several future products, magnifying short-term savings while also magnifying any initial misalignment with value-based pricing. Reimbursement decisions inside the programme become increasingly path-dependent. System dynamics shift accordingly. Portfolio choices may tilt toward disease areas where the inheritance of low anchors is less severe, rather than toward the greatest potential health gain. Although the source material does not address ethnic heterogeneity, weight regain or cardiometabolic outcomes in detail, the same mechanical pressure will apply to any class in which earlier prices sit well below differentiated clinical value.

Implications for Pricing Strategies and Market Access

Pricing strategies must treat prior MFP anchors as highly sticky. Launch sequencing, indication ordering and evidence generation plans should identify, for every pipeline asset, the plausible set of already-negotiated alternatives that could supply the opening figure, including those whose clinical overlap is only partial. Market access directors will need scenario models that separate the mechanical effect of the inherited anchor from the residual margin that clinical differentiation might still influence. Because the process offers limited scope for later upward revision when new data emerge, the first negotiation becomes decisive. Manufacturers and payers alike should expect growing divergence between Medicare net prices and those realised in systems that still price differentiation more directly. Transparent internal value frameworks remain essential; without them, companies cannot articulate why a medicine warrants adjustment above a loosely related anchor, nor can they brief affiliates operating under different national rules.

Actionable Recommendations for Decision-Makers

HEOR and market access leaders should rebuild forecast models to surface every relevant prior MFP that might set the starting point and should stress-test evidence plans against the possibility that only a qualitative residual remains contestable. Pricing teams ought to construct explicit reservation analyses that incorporate the real statutory backstop while preparing external materials that cleanly separate incremental clinical value from anchor mechanics. Health technology assessment bodies and academic groups can help by publishing clear mappings from comparative effectiveness and cost offsets to price implications, thereby creating external reference points. Programme policymakers retain rule-making latitude to require disclosure of which benchmark was chosen and the approximate weight of subsequent adjustments, to treat earlier MFPs as evidence rather than automatic floors, to reverse the order so that clinical difference is considered before a price is allowed to set the floor, and to issue a public rubric that quantifies how evidence moves price. Health-system budget holders should model multi-year propagation so that projected savings are not assumed to equal value alignment.

Preserving the Link Between Benefit and Price

Prior MFP anchors now shape long-term price trajectories at least as powerfully as new clinical evidence. The central strategic takeaway is that process architecture itself has become a primary determinant of whether Medicare prices retain any transparent connection to therapeutic worth. Greater disclosure, re-ordering of analytical steps and quantified value adjustments remain possible within existing statutory bounds. Leadership teams that treat the issue merely as a tactical negotiation problem will under-prepare. Those that recognise it as a structural redesign of the price-value relationship will be better placed to protect patient access, maintain coherent reimbursement decisions and sustain the incentives required for continued innovation across the medicines landscape.